Global and United States Neuroendocrine Tumor Drug In-Depth Research Report 2017-2022

Published: Dec, 2017 | Pages: 119 | Publisher: US Market Insight (UMI)
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

The report is based on the market historical data from 2012 to 2016 and forecast the market trend from 2017 to 2022.

This report focuses on the U.S. market and presents volume and value of market share by players, by regions, by product type, by consumers and also changes in prices. As an in-depth report, it covers all details inside analysis and opinions in Neuroendocrine Tumor Drug industry.

Major Companies
Eisai
Exelixis, Inc.
Foresee Pharmaceuticals, LLC
Hutchison MediPharma Limited
Intezyne, Inc
INVENT Pharmaceuticals, Inc.
Ipsen S.A.
Jiangsu Hengrui Medicine Co., Ltd.
Karyopharm Therapeutics, Inc.
Lexicon Pharmaceuticals, Inc.
Midatech Pharma Plc .
Millennium Pharmaceuticals, Inc.
MolMed S.p.A.
Northwest Biotherapeutics, Inc.
Novartis AG
OctreoPharm Sciences GmbH
OXiGENE, Inc.

Key Regions
North America
United States
California
Texas
New York
Others
Canada
Latin America
Mexico
Brazil
Argentina
Others
Europe
Germany
United Kingdom
France
Italy
Spain
Russia
Netherland
Others
Asia & Pacific
China
Japan
India
Korea
Australia
Southeast Asia
Indonesia
Thailand
Philippines
Vietnam
Singapore
Malaysia
Others
Africa & Middle East
South Africa
Egypt
Turkey
Saudi Arabia
Iran
Others

Main types of products
Neuroendocrine Tumor Drug Market, byOR protein inhibitors
Neuroendocrine Tumor Drug Market, byrosine kinase 3 inhibitors
Neuroendocrine Tumor Drug Market, bymatostatin receptor antagonist
Neuroendocrine Tumor Drug Market, byowth hormone releasing factor
Neuroendocrine Tumor Drug Market, bymatostatin receptor agonists

Neuroendocrine Tumor Drug Market, by Key Consumers
Hospital
Clinic
Others

 Table of Contents

Global and United States Neuroendocrine Tumor Drug In-Depth Research Report 2017-2022
Chapter One Global Neuroendocrine Tumor Drug Market Overview
    1.1 Global Neuroendocrine Tumor Drug Market Sales Volume Revenue and Price 2012-2017
    1.2 Neuroendocrine Tumor Drug, by R protein inhibitors 2012-2017
        1.2.1 Global Neuroendocrine Tumor Drug Sales Market Share by R protein inhibitors 2012-2017
        1.2.2 Global Neuroendocrine Tumor Drug Revenue Market Share by R protein inhibitors 2012-2017
        1.2.3 Global Neuroendocrine Tumor Drug Price by R protein inhibitors 2012-2017
        1.2.4 
        1.2.5 
    1.3 Neuroendocrine Tumor Drug, by osine kinase 3 inhibitors 2012-2017
        1.3.1 Global Neuroendocrine Tumor Drug Sales Market Share by osine kinase 3 inhibitors 2012-2017
        1.3.2 Global Neuroendocrine Tumor Drug Revenue Market Share by osine kinase 3 inhibitors 2012-2017
        1.3.3 Global Neuroendocrine Tumor Drug Price by osine kinase 3 inhibitors 2012-2017
        1.3.4 
        1.3.5 
    1.4 Neuroendocrine Tumor Drug, by atostatin receptor antagonists 2012-2017
        1.4.1 Global Neuroendocrine Tumor Drug Sales Market Share by atostatin receptor antagonists 2012-2017
        1.4.2 Global Neuroendocrine Tumor Drug Revenue Market Share by atostatin receptor antagonists 2012-2017
        1.4.3 Global Neuroendocrine Tumor Drug Price by atostatin receptor antagonists 2012-2017
        1.4.4 
        1.4.5 
    1.5 Neuroendocrine Tumor Drug, by wth hormone releasing factor a 2012-2017
        1.5.1 Global Neuroendocrine Tumor Drug Sales Market Share by wth hormone releasing factor a 2012-2017
        1.5.2 Global Neuroendocrine Tumor Drug Revenue Market Share by wth hormone releasing factor a 2012-2017
        1.5.3 Global Neuroendocrine Tumor Drug Price by wth hormone releasing factor a 2012-2017
        1.5.4 
        1.5.5 
    1.6 Neuroendocrine Tumor Drug, by atostatin receptor agonists 2012-2017
        1.6.1 Global Neuroendocrine Tumor Drug Sales Market Share by atostatin receptor agonists 2012-2017
        1.6.2 Global Neuroendocrine Tumor Drug Revenue Market Share by atostatin receptor agonists 2012-2017
        1.6.3 Global Neuroendocrine Tumor Drug Price by atostatin receptor agonists 2012-2017
        1.6.4 
        1.6.5 

Chapter Two United States Neuroendocrine Tumor Drug Market Overview
    2.1 United States Neuroendocrine Tumor Drug Market Sales Volume Revenue and Price 2012-2017
    2.2 Neuroendocrine Tumor Drug, by R protein inhibitors 2012-2017
        2.2.1 United States Neuroendocrine Tumor Drug Sales Market Share by R protein inhibitors 2012-2017
        2.2.2 United States Neuroendocrine Tumor Drug Revenue Market Share by R protein inhibitors 2012-2017
        2.2.3 United States Neuroendocrine Tumor Drug Price by R protein inhibitors 2012-2017
        2.2.4 
        2.2.5 
    2.3 Neuroendocrine Tumor Drug, by osine kinase 3 inhibitors 2012-2017
        2.3.1 United States Neuroendocrine Tumor Drug Sales Market Share by osine kinase 3 inhibitors 2012-2017
        2.3.2 United States Neuroendocrine Tumor Drug Revenue Market Share by osine kinase 3 inhibitors 2012-2017
        2.3.3 United States Neuroendocrine Tumor Drug Price by osine kinase 3 inhibitors 2012-2017
        2.3.4 
        2.3.5 
    2.4 Neuroendocrine Tumor Drug, by atostatin receptor antagonists 2012-2017
        2.4.1 United States Neuroendocrine Tumor Drug Sales Market Share by atostatin receptor antagonists 2012-2017
        2.4.2 United States Neuroendocrine Tumor Drug Revenue Market Share by atostatin receptor antagonists 2012-2017
        2.4.3 United States Neuroendocrine Tumor Drug Price by atostatin receptor antagonists 2012-2017
        2.4.4 
        2.4.5 
    2.5 Neuroendocrine Tumor Drug, by wth hormone releasing factor a 2012-2017
        2.5.1 United States Neuroendocrine Tumor Drug Sales Market Share by wth hormone releasing factor a 2012-2017
        2.5.2 United States Neuroendocrine Tumor Drug Revenue Market Share by wth hormone releasing factor a 2012-2017
        2.5.3 United States Neuroendocrine Tumor Drug Price by wth hormone releasing factor a 2012-2017
        2.5.4 
        2.5.5 
    2.6 Neuroendocrine Tumor Drug, by atostatin receptor agonists 2012-2017
        2.6.1 United States Neuroendocrine Tumor Drug Sales Market Share by atostatin receptor agonists 2012-2017
        2.6.2 United States Neuroendocrine Tumor Drug Revenue Market Share by atostatin receptor agonists 2012-2017
        2.6.3 United States Neuroendocrine Tumor Drug Price by atostatin receptor agonists 2012-2017
        2.6.4 
        2.6.5 

Chapter Three Neuroendocrine Tumor Drug by Regions 2012-2017
    3.1 Global Neuroendocrine Tumor Drug Sales Market Share by Regions 2012-2017
    3.2 Global Neuroendocrine Tumor Drug Revenue Market Share by Regions 2012-2017
    3.3 Global Neuroendocrine Tumor Drug Price by Regions 2012-2017
    3.4 North America
        3.4.1 United States
            3.4.1.1 California
            3.4.1.2 Texas
            3.4.1.3 New York
            3.4.1.4 Others in United States
        3.4.2 Canada
    3.5 Latin America
        3.5.1 Mexico
        3.5.2 Brazil
        3.5.3 Argentina
        3.5.4 Others in Latin America
    3.6 Europe
        3.6.1 Germany
        3.6.2 United Kingdom
        3.6.3 France
        3.6.4 Italy
        3.6.5 Spain
        3.6.6 Russia
        3.6.7 Netherland
        3.6.8 Others in Europe
    3.7 Asia & Pacific
        3.7.1 China
        3.7.2 Japan
        3.7.3 India
        3.7.4 Korea
        3.7.5 Australia
        3.7.6 Southeast Asia
            3.7.6.1 Indonesia
            3.7.6.2 Thailand
            3.7.6.3 Philippines
            3.7.6.4 Vietnam
            3.7.6.5 Singapore
            3.7.6.6 Malaysia
            3.7.6.7 Others in Southeast Asia
    3.8 Africa & Middle East
        3.8.1 South Africa
        3.8.2 Egypt
        3.8.3 Turkey
        3.8.4 Saudi Arabia
        3.8.5 Iran
        3.8.6 Others in Africa & Middle East

Chapter Four Global Neuroendocrine Tumor Drug by Companies 2012-2017
    4.1 Global Neuroendocrine Tumor Drug Sales Volume Market Share by Companies 2012-2017
    4.2 Global Neuroendocrine Tumor Drug Revenue Share by Companies 2012-2017
    4.3 Global Top Companies Neuroendocrine Tumor Drug Key Product Model and Market Performance
    4.4 Global Top Companies Neuroendocrine Tumor Drug Key Target Consumers and Market Performance

Chapter Five United States Neuroendocrine Tumor Drug by Companies 2012-2017
    5.1 United States Neuroendocrine Tumor Drug Sales Volume Market Share by Companies 2012-2017
    5.2 United States Neuroendocrine Tumor Drug Revenue Share by Companies 2012-2017
    5.3 United States Top Companies Neuroendocrine Tumor Drug Key Product Model and Market Performance
    5.4 United States Top Companies Neuroendocrine Tumor Drug Key Target Consumers and Market Performance

Chapter Six Global Neuroendocrine Tumor Drug by Consumer 2012-2017
    6.1 Global Neuroendocrine Tumor Drug Sales Market Share by Consumer 2012-2017
    6.2 Hospital
    6.3 Clinic
    6.4 Others
    6.5 Consuming Habit and Preference

Chapter Seven Global Neuroendocrine Tumor Drug by Consumer 2012-2017
    7.1 Global Neuroendocrine Tumor Drug Sales Market Share by Consumer 2012-2017
    7.2 Hospital
    7.3 Clinic
    7.4 Others
    7.5 Consuming Habit and Preference

Chapter Eight Top Companies Profile
    8.1 Eisai
        8.1.1 Eisai Company Details and Competitors
        8.1.2 Eisai Key Neuroendocrine Tumor Drug Models and Performance
        8.1.3 Eisai Neuroendocrine Tumor Drug Business SWOT Analysis and Forecast
        8.1.4 Eisai Neuroendocrine Tumor Drug Sales Volume Revenue Price Cost and Gross Margin
    8.2 Exelixis, Inc.
        8.2.1 Exelixis, Inc. Company Details and Competitors
        8.2.2 Exelixis, Inc. Key Neuroendocrine Tumor Drug Models and Performance
        8.2.3 Exelixis, Inc. Neuroendocrine Tumor Drug Business SWOT Analysis and Forecast
        8.2.4 Exelixis, Inc. Neuroendocrine Tumor Drug Sales Volume Revenue Price Cost and Gross Margin
    8.3 Foresee Pharmaceuticals, LLC
        8.3.1 Foresee Pharmaceuticals, LLC Company Details and Competitors
        8.3.2 Foresee Pharmaceuticals, LLC Key Neuroendocrine Tumor Drug Models and Performance
        8.3.3 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Business SWOT Analysis and Forecast
        8.3.4 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales Volume Revenue Price Cost and Gross Margin
    8.4 Hutchison MediPharma Limited
        8.4.1 Hutchison MediPharma Limited Company Details and Competitors
        8.4.2 Hutchison MediPharma Limited Key Neuroendocrine Tumor Drug Models and Performance
        8.4.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Business SWOT Analysis and Forecast
        8.4.4 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales Volume Revenue Price Cost and Gross Margin
    8.5 Intezyne, Inc
        8.5.1 Intezyne, Inc Company Details and Competitors
        8.5.2 Intezyne, Inc Key Neuroendocrine Tumor Drug Models and Performance
        8.5.3 Intezyne, Inc Neuroendocrine Tumor Drug Business SWOT Analysis and Forecast
        8.5.4 Intezyne, Inc Neuroendocrine Tumor Drug Sales Volume Revenue Price Cost and Gross Margin
    8.6 INVENT Pharmaceuticals, Inc.
        8.6.1 INVENT Pharmaceuticals, Inc. Company Details and Competitors
        8.6.2 INVENT Pharmaceuticals, Inc. Key Neuroendocrine Tumor Drug Models and Performance
        8.6.3 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Business SWOT Analysis and Forecast
        8.6.4 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales Volume Revenue Price Cost and Gross Margin
    8.7 Ipsen S.A.
        8.7.1 Ipsen S.A. Company Details and Competitors
        8.7.2 Ipsen S.A. Key Neuroendocrine Tumor Drug Models and Performance
        8.7.3 Ipsen S.A. Neuroendocrine Tumor Drug Business SWOT Analysis and Forecast
        8.7.4 Ipsen S.A. Neuroendocrine Tumor Drug Sales Volume Revenue Price Cost and Gross Margin
    8.8 Jiangsu Hengrui Medicine Co., Ltd.
        8.8.1 Jiangsu Hengrui Medicine Co., Ltd. Company Details and Competitors
        8.8.2 Jiangsu Hengrui Medicine Co., Ltd. Key Neuroendocrine Tumor Drug Models and Performance
        8.8.3 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Business SWOT Analysis and Forecast
        8.8.4 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales Volume Revenue Price Cost and Gross Margin
    8.9 Karyopharm Therapeutics, Inc.
        8.9.1 Karyopharm Therapeutics, Inc. Company Details and Competitors
        8.9.2 Karyopharm Therapeutics, Inc. Key Neuroendocrine Tumor Drug Models and Performance
        8.9.3 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Business SWOT Analysis and Forecast
        8.9.4 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales Volume Revenue Price Cost and Gross Margin
    8.10 Lexicon Pharmaceuticals, Inc.
        8.10.1 Lexicon Pharmaceuticals, Inc. Company Details and Competitors
        8.10.2 Lexicon Pharmaceuticals, Inc. Key Neuroendocrine Tumor Drug Models and Performance
        8.10.3 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Business SWOT Analysis and Forecast
        8.10.4 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales Volume Revenue Price Cost and Gross Margin
    8.11 Midatech Pharma Plc .
    8.12 Millennium Pharmaceuticals, Inc.
    8.13 MolMed S.p.A.
    8.14 Northwest Biotherapeutics, Inc.
    8.15 Novartis AG
    8.16 OctreoPharm Sciences GmbH
    8.17 OXiGENE, Inc.

Chapter Nine Industry Chain and Supply Chain
    9.1 Neuroendocrine Tumor Drug Industry Chain Structure
        9.1.1 R&D
        9.1.2 Raw Materials (Components)
        9.1.3 Manufacturing Plants
        9.1.4 Regional Trading (Import Export and Local Sales)
        9.1.5 Online Sales Channel
        9.1.6 Offline Channel
        9.1.7 End Users
    9.2 Neuroendocrine Tumor Drug Manufacturing
        9.2.1 Key Components
        9.2.2 Assembly Manufacturing
    9.3 Consumer Preference
    9.4 Behavioral Habits
    9.5 Marketing Environment

Chapter Ten Global Neuroendocrine Tumor Drug Market Size (Sales and Revenue) Forecast (2017-2022)
    10.1 Global Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD) Forecast (2017-2022)
    10.2 Global Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by Regions (2017-2022)
    10.3 Global Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by Application (2017-2022)
    10.4 Global Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by R protein inhibitors (2017-2022)
    10.5 Global Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by osine kinase 3 inhibitors (2017-2022)
    10.6 Global Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by atostatin receptor antagonists (2017-2022)
    10.7 Global Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by wth hormone releasing factor a (2017-2022)
    10.8 Global Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by atostatin receptor agonists (2017-2022)

Chapter Eleven United States Neuroendocrine Tumor Drug Market Size (Sales and Revenue) Forecast (2017-2022)
    11.1 United States Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD) Forecast (2017-2022)
    11.2 United States Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by Regions (2017-2022)
    11.3 United States Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by Application (2017-2022)
    11.4 United States Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by R protein inhibitors (2017-2022)
    11.5 United States Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by osine kinase 3 inhibitors (2017-2022)
    11.6 United States Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by atostatin receptor antagonists (2017-2022)
    11.7 United States Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by wth hormone releasing factor a (2017-2022)
    11.8 United States Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by atostatin receptor agonists (2017-2022)

Chapter Twelve Development Trend and Research Conclusion
    12.1 Development Trend
    12.2 Research Conclusion

Chapter Thirteen Methodology and Data Source
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer

List of Tables and Figures

    Table Global Neuroendocrine Tumor Drug Sales Volume (K Pcs), Revenue (Million USD) and Price (USD/Pcs)(2012-2017)
    Figure Global Neuroendocrine Tumor Drug Revenue (Million USD) and Growth Rate (2012-2017)
    Figure Global Neuroendocrine Tumor Drug Sales Volume (K Pcs) and Growth Rate (2012-2017)
    Table Global Neuroendocrine Tumor Drug Sales (K Pcs) by R protein inhibitors (2012-2017)
    Table Global Neuroendocrine Tumor Drug Sales Market Share by R protein inhibitors (2012-2017)
    Figure Global Neuroendocrine Tumor Drug Sales Market Share by R protein inhibitors in 2016
    Table Global Neuroendocrine Tumor Drug Revenue (Million USD) by R protein inhibitors (2012-2017)
    Table Global Neuroendocrine Tumor Drug Revenue Market Share by R protein inhibitors (2012-2017)
    Figure Global Neuroendocrine Tumor Drug Revenue Market Share by R protein inhibitors in 2016
    Table Global Neuroendocrine Tumor Drug Price (USD/Pcs) by R protein inhibitors (2012-2017)
    Table Global Neuroendocrine Tumor Drug Sales (K Pcs) by osine kinase 3 inhibitors (2012-2017)
    Table Global Neuroendocrine Tumor Drug Sales Market Share by osine kinase 3 inhibitors (2012-2017)
    Figure Global Neuroendocrine Tumor Drug Sales Market Share by osine kinase 3 inhibitors in 2016
    Table Global Neuroendocrine Tumor Drug Revenue (Million USD) by osine kinase 3 inhibitors (2012-2017)
    Table Global Neuroendocrine Tumor Drug Revenue Market Share by osine kinase 3 inhibitors (2012-2017)
    Figure Global Neuroendocrine Tumor Drug Revenue Market Share by osine kinase 3 inhibitors in 2016
    Table Global Neuroendocrine Tumor Drug Price (USD/Pcs) by osine kinase 3 inhibitors (2012-2017)
    Table Global Neuroendocrine Tumor Drug Sales (K Pcs) by atostatin receptor antagonists (2012-2017)
    Table Global Neuroendocrine Tumor Drug Sales Market Share by atostatin receptor antagonists (2012-2017)
    Figure Global Neuroendocrine Tumor Drug Sales Market Share by atostatin receptor antagonists in 2016
    Table Global Neuroendocrine Tumor Drug Revenue (Million USD) by atostatin receptor antagonists (2012-2017)
    Table Global Neuroendocrine Tumor Drug Revenue Market Share by atostatin receptor antagonists (2012-2017)
    Figure Global Neuroendocrine Tumor Drug Revenue Market Share by atostatin receptor antagonists in 2016
    Table Global Neuroendocrine Tumor Drug Price (USD/Pcs) by atostatin receptor antagonists (2012-2017)
    Table Global Neuroendocrine Tumor Drug Sales (K Pcs) by wth hormone releasing factor a (2012-2017)
    Table Global Neuroendocrine Tumor Drug Sales Market Share by wth hormone releasing factor a (2012-2017)
    Figure Global Neuroendocrine Tumor Drug Sales Market Share by wth hormone releasing factor a in 2016
    Table Global Neuroendocrine Tumor Drug Revenue (Million USD) by wth hormone releasing factor a (2012-2017)
    Table Global Neuroendocrine Tumor Drug Revenue Market Share by wth hormone releasing factor a (2012-2017)
    Figure Global Neuroendocrine Tumor Drug Revenue Market Share by wth hormone releasing factor a in 2016
    Table Global Neuroendocrine Tumor Drug Price (USD/Pcs) by wth hormone releasing factor a (2012-2017)
    Table Global Neuroendocrine Tumor Drug Sales (K Pcs) by atostatin receptor agonists (2012-2017)
    Table Global Neuroendocrine Tumor Drug Sales Market Share by atostatin receptor agonists (2012-2017)
    Figure Global Neuroendocrine Tumor Drug Sales Market Share by atostatin receptor agonists in 2016
    Table Global Neuroendocrine Tumor Drug Revenue (Million USD) by atostatin receptor agonists (2012-2017)
    Table Global Neuroendocrine Tumor Drug Revenue Market Share by atostatin receptor agonists (2012-2017)
    Figure Global Neuroendocrine Tumor Drug Revenue Market Share by atostatin receptor agonists in 2016
    Table Global Neuroendocrine Tumor Drug Price (USD/Pcs) by atostatin receptor agonists (2012-2017)
    Figure United States Neuroendocrine Tumor Drug Revenue (Million USD) and Growth Rate (2012-2017)
    Figure United States Neuroendocrine Tumor Drug Sales Volume (K Pcs) and Growth Rate (2012-2017)
    Table United States Neuroendocrine Tumor Drug Sales (K Pcs) by R protein inhibitors (2012-2017)
    Table United States Neuroendocrine Tumor Drug Sales Market Share by R protein inhibitors (2012-2017)
    Figure United States Neuroendocrine Tumor Drug Sales Market Share by R protein inhibitors in 2016
    Table United States Neuroendocrine Tumor Drug Revenue (Million USD) by R protein inhibitors (2012-2017)
    Table United States Neuroendocrine Tumor Drug Revenue Market Share by R protein inhibitors (2012-2017)
    Figure United States Neuroendocrine Tumor Drug Revenue Market Share by R protein inhibitors in 2016
    Table United States Neuroendocrine Tumor Drug Price (USD/Pcs) by R protein inhibitors (2012-2017)
    Table United States Neuroendocrine Tumor Drug Sales (K Pcs) by osine kinase 3 inhibitors (2012-2017)
    Table United States Neuroendocrine Tumor Drug Sales Market Share by osine kinase 3 inhibitors (2012-2017)
    Figure United States Neuroendocrine Tumor Drug Sales Market Share by osine kinase 3 inhibitors in 2016
    Table United States Neuroendocrine Tumor Drug Revenue (Million USD) by osine kinase 3 inhibitors (2012-2017)
    Table United States Neuroendocrine Tumor Drug Revenue Market Share by osine kinase 3 inhibitors (2012-2017)
    Figure United States Neuroendocrine Tumor Drug Revenue Market Share by osine kinase 3 inhibitors in 2016
    Table United States Neuroendocrine Tumor Drug Price (USD/Pcs) by osine kinase 3 inhibitors (2012-2017)
    Table United States Neuroendocrine Tumor Drug Sales (K Pcs) by atostatin receptor antagonists (2012-2017)
    Table United States Neuroendocrine Tumor Drug Sales Market Share by atostatin receptor antagonists (2012-2017)
    Figure United States Neuroendocrine Tumor Drug Sales Market Share by atostatin receptor antagonists in 2016
    Table United States Neuroendocrine Tumor Drug Revenue (Million USD) by atostatin receptor antagonists (2012-2017)
    Table United States Neuroendocrine Tumor Drug Revenue Market Share by atostatin receptor antagonists (2012-2017)
    Figure United States Neuroendocrine Tumor Drug Revenue Market Share by atostatin receptor antagonists in 2016
    Table United States Neuroendocrine Tumor Drug Price (USD/Pcs) by atostatin receptor antagonists (2012-2017)
    Table United States Neuroendocrine Tumor Drug Sales (K Pcs) by wth hormone releasing factor a (2012-2017)
    Table United States Neuroendocrine Tumor Drug Sales Market Share by wth hormone releasing factor a (2012-2017)
    Figure United States Neuroendocrine Tumor Drug Sales Market Share by wth hormone releasing factor a in 2016
    Table United States Neuroendocrine Tumor Drug Revenue (Million USD) by wth hormone releasing factor a (2012-2017)
    Table United States Neuroendocrine Tumor Drug Revenue Market Share by wth hormone releasing factor a (2012-2017)
    Figure United States Neuroendocrine Tumor Drug Revenue Market Share by wth hormone releasing factor a in 2016
    Table United States Neuroendocrine Tumor Drug Price (USD/Pcs) by wth hormone releasing factor a (2012-2017)
    Table United States Neuroendocrine Tumor Drug Sales (K Pcs) by atostatin receptor agonists (2012-2017)
    Table United States Neuroendocrine Tumor Drug Sales Market Share by atostatin receptor agonists (2012-2017)
    Figure United States Neuroendocrine Tumor Drug Sales Market Share by atostatin receptor agonists in 2016
    Table United States Neuroendocrine Tumor Drug Revenue (Million USD) by atostatin receptor agonists (2012-2017)
    Table United States Neuroendocrine Tumor Drug Revenue Market Share by atostatin receptor agonists (2012-2017)
    Figure United States Neuroendocrine Tumor Drug Revenue Market Share by atostatin receptor agonists in 2016
    Table United States Neuroendocrine Tumor Drug Price (USD/Pcs) by atostatin receptor agonists (2012-2017)
    Table Global Neuroendocrine Tumor Drug Sales (K Pcs) by Regions (2012-2017)
    Table Global Neuroendocrine Tumor Drug Sales Share by Regions (2012-2017)
    Figure Global Neuroendocrine Tumor Drug Sales Market Share by Regions in 2016
    Figure Global Neuroendocrine Tumor Drug Sales Market Share by Regions in 2017
    Table Global Neuroendocrine Tumor Drug Revenue (Million USD) and Market Share by Regions (2012-2017)
    Table Global Neuroendocrine Tumor Drug Revenue Market Share by Regions (2012-2017)
    Figure Global Neuroendocrine Tumor Drug Revenue Market Share by Regions in 2016
    Figure Global Neuroendocrine Tumor Drug Revenue Market Share by Regions in 2017
    Table Global Neuroendocrine Tumor Drug Price (USD/Pcs) by Regions (2012-2017)
    Table North America Neuroendocrine Tumor Drug Sales (K Pcs) by Regions (2012-2017)
    Table North America Neuroendocrine Tumor Drug Revenue (Million USD) by Regions (2012-2017)
    Figure North America Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
    Table United States Neuroendocrine Tumor Drug Sales (K Pcs) by Regions (2012-2017)
    Table United States Neuroendocrine Tumor Drug Revenue (Million USD) by Regions (2012-2017)
    Figure United States Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
    Table Latin America Neuroendocrine Tumor Drug Sales (K Pcs) by Regions (2012-2017)
    Table Latin America Neuroendocrine Tumor Drug Revenue (Million USD) by Regions (2012-2017)
    Figure Latin America Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
    Table Europe Neuroendocrine Tumor Drug Sales (K Pcs) by Regions (2012-2017)
    Table Europe Neuroendocrine Tumor Drug Revenue (Million USD) by Regions (2012-2017)
    Figure Europe Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
    Table Asia & Pacific Neuroendocrine Tumor Drug Sales (K Pcs) by Regions (2012-2017)
    Table Asia & Pacific Neuroendocrine Tumor Drug Revenue (Million USD) by Regions (2012-2017)
    Figure Asia & Pacific Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
    Table Africa & Middle East Neuroendocrine Tumor Drug Sales (K Pcs) by Regions (2012-2017)
    Table Africa & Middle East Neuroendocrine Tumor Drug Revenue (Million USD) by Regions (2012-2017)
    Figure Africa & Middle East Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
    Table Global Neuroendocrine Tumor Drug Sales Volume (K Pcs) by Major Companies (2012-2017)
    Table Global Neuroendocrine Tumor Drug Sales Volume Market Share by Major Companies (2012-2017)
    Figure Global Neuroendocrine Tumor Drug Sales Volume Market Share by Major Companies 2016
    Figure Global Neuroendocrine Tumor Drug Sales Volume Market Share by Major Companies 2017
    Table Global Neuroendocrine Tumor Drug Revenue (Million USD) by Major Companies (2012-2017)
    Table Global Neuroendocrine Tumor Drug Revenue Market Share by Major Companies (2012-2017)
    Figure Global Neuroendocrine Tumor Drug Revenue Market Share by Major Companies 2016
    Figure Global Neuroendocrine Tumor Drug Revenue Market Share by Major Companies 2017
    Table Global Top Companies Key Product Model and Market Performance
    Table Global Top Companies Key Target Consumers and Market Performance
    Table United States Neuroendocrine Tumor Drug Sales Volume (K Pcs) by Top Companies (2012-2017)
    Table United States Neuroendocrine Tumor Drug Sales Volume Market Share by Top Companies (2012-2017)
    Figure United States Neuroendocrine Tumor Drug Sales Volume Market Share by Top Companies 2016
    Figure United States Neuroendocrine Tumor Drug Sales Volume Market Share by Top Companies 2017
    Table United States Neuroendocrine Tumor Drug Revenue (Million USD) by Top Companies (2012-2017)
    Table United States Neuroendocrine Tumor Drug Revenue Market Share by Top Companies (2012-2017)
    Figure United States Neuroendocrine Tumor Drug Revenue Market Share by Top Companies 2016
    Figure United States Neuroendocrine Tumor Drug Revenue Market Share by Top Companies 2017
    Table United States Top Companies Key Product Model and Market Performance
    Table United States Top Companies Key Target Consumers and Market Performance
    Table Global Neuroendocrine Tumor Drug Sales (K Pcs) by Consumer (2012-2017)
    Figure Global Neuroendocrine Tumor Drug Sales Market Share by Consumer (2012-2017)
    Figure Global Neuroendocrine Tumor Drug Sales Market Share by Consumer in 2016
    Figure Global Hospital Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Global Clinic Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Global Others Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
    Table United States Neuroendocrine Tumor Drug Sales (K Pcs) by Consumer (2012-2017)
    Figure United States Neuroendocrine Tumor Drug Sales Market Share by Consumer (2012-2017)
    Figure United States Neuroendocrine Tumor Drug Sales Market Share by Consumer in 2016
    Figure United States Hospital Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
    Figure United States Clinic Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
    Figure United States Others Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
    Table Eisai Company Details and Competitors
    Table Eisai Key Neuroendocrine Tumor Drug Models and Performance
    Table Eisai Neuroendocrine Tumor Drug Business SWOT Analysis and Forecast
    Table Eisai Neuroendocrine Tumor Drug Output (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Figure Eisai Neuroendocrine Tumor Drug Sales (Million Unit) and Growth Rate (%)(2012-2017)
    Figure Eisai Neuroendocrine Tumor Drug Sales Market Share (%) in Global (2012-2017)
    Figure Eisai Neuroendocrine Tumor Drug Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
    Figure Eisai Neuroendocrine Tumor Drug Revenue Market Share (%) in Global (2012-2017)
    Table Exelixis, Inc. Company Details and Competitors
    Table Exelixis, Inc. Key Neuroendocrine Tumor Drug Models and Performance
    Table Exelixis, Inc. Neuroendocrine Tumor Drug Business SWOT Analysis and Forecast
    Table Exelixis, Inc. Neuroendocrine Tumor Drug Output (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Figure Exelixis, Inc. Neuroendocrine Tumor Drug Sales (Million Unit) and Growth Rate (%)(2012-2017)
    Figure Exelixis, Inc. Neuroendocrine Tumor Drug Sales Market Share (%) in Global (2012-2017)
    Figure Exelixis, Inc. Neuroendocrine Tumor Drug Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
    Figure Exelixis, Inc. Neuroendocrine Tumor Drug Revenue Market Share (%) in Global (2012-2017)
    Table Foresee Pharmaceuticals, LLC Company Details and Competitors
    Table Foresee Pharmaceuticals, LLC Key Neuroendocrine Tumor Drug Models and Performance
    Table Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Business SWOT Analysis and Forecast
    Table Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Output (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Figure Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales (Million Unit) and Growth Rate (%)(2012-2017)
    Figure Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales Market Share (%) in Global (2012-2017)
    Figure Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
    Figure Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Revenue Market Share (%) in Global (2012-2017)
    Table Hutchison MediPharma Limited Company Details and Competitors
    Table Hutchison MediPharma Limited Key Neuroendocrine Tumor Drug Models and Performance
    Table Hutchison MediPharma Limited Neuroendocrine Tumor Drug Business SWOT Analysis and Forecast
    Table Hutchison MediPharma Limited Neuroendocrine Tumor Drug Output (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Figure Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales (Million Unit) and Growth Rate (%)(2012-2017)
    Figure Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales Market Share (%) in Global (2012-2017)
    Figure Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
    Figure Hutchison MediPharma Limited Neuroendocrine Tumor Drug Revenue Market Share (%) in Global (2012-2017)
    Table Intezyne, Inc Company Details and Competitors
    Table Intezyne, Inc Key Neuroendocrine Tumor Drug Models and Performance
    Table Intezyne, Inc Neuroendocrine Tumor Drug Business SWOT Analysis and Forecast
    Table Intezyne, Inc Neuroendocrine Tumor Drug Output (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Figure Intezyne, Inc Neuroendocrine Tumor Drug Sales (Million Unit) and Growth Rate (%)(2012-2017)
    Figure Intezyne, Inc Neuroendocrine Tumor Drug Sales Market Share (%) in Global (2012-2017)
    Figure Intezyne, Inc Neuroendocrine Tumor Drug Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
    Figure Intezyne, Inc Neuroendocrine Tumor Drug Revenue Market Share (%) in Global (2012-2017)
    Table INVENT Pharmaceuticals, Inc. Company Details and Competitors
    Table INVENT Pharmaceuticals, Inc. Key Neuroendocrine Tumor Drug Models and Performance
    Table INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Business SWOT Analysis and Forecast
    Table INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Output (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Figure INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (Million Unit) and Growth Rate (%)(2012-2017)
    Figure INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales Market Share (%) in Global (2012-2017)
    Figure INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
    Figure INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Revenue Market Share (%) in Global (2012-2017)
    Table Ipsen S.A. Company Details and Competitors
    Table Ipsen S.A. Key Neuroendocrine Tumor Drug Models and Performance
    Table Ipsen S.A. Neuroendocrine Tumor Drug Business SWOT Analysis and Forecast
    Table Ipsen S.A. Neuroendocrine Tumor Drug Output (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Figure Ipsen S.A. Neuroendocrine Tumor Drug Sales (Million Unit) and Growth Rate (%)(2012-2017)
    Figure Ipsen S.A. Neuroendocrine Tumor Drug Sales Market Share (%) in Global (2012-2017)
    Figure Ipsen S.A. Neuroendocrine Tumor Drug Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
    Figure Ipsen S.A. Neuroendocrine Tumor Drug Revenue Market Share (%) in Global (2012-2017)
    Table Jiangsu Hengrui Medicine Co., Ltd. Company Details and Competitors
    Table Jiangsu Hengrui Medicine Co., Ltd. Key Neuroendocrine Tumor Drug Models and Performance
    Table Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Business SWOT Analysis and Forecast
    Table Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Output (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Figure Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales (Million Unit) and Growth Rate (%)(2012-2017)
    Figure Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales Market Share (%) in Global (2012-2017)
    Figure Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
    Figure Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Revenue Market Share (%) in Global (2012-2017)
    Table Karyopharm Therapeutics, Inc. Company Details and Competitors
    Table Karyopharm Therapeutics, Inc. Key Neuroendocrine Tumor Drug Models and Performance
    Table Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Business SWOT Analysis and Forecast
    Table Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Output (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Figure Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales (Million Unit) and Growth Rate (%)(2012-2017)
    Figure Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales Market Share (%) in Global (2012-2017)
    Figure Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
    Figure Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Revenue Market Share (%) in Global (2012-2017)
    Table Lexicon Pharmaceuticals, Inc. Company Details and Competitors
    Table Lexicon Pharmaceuticals, Inc. Key Neuroendocrine Tumor Drug Models and Performance
    Table Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Business SWOT Analysis and Forecast
    Table Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Output (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Figure Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (Million Unit) and Growth Rate (%)(2012-2017)
    Figure Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales Market Share (%) in Global (2012-2017)
    Figure Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
    Figure Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Revenue Market Share (%) in Global (2012-2017)
    Table Midatech Pharma Plc . Company Details and Competitors
    Table Millennium Pharmaceuticals, Inc. Company Details and Competitors
    Table MolMed S.p.A. Company Details and Competitors
    Table Northwest Biotherapeutics, Inc. Company Details and Competitors
    Table Novartis AG Company Details and Competitors
    Table OctreoPharm Sciences GmbH Company Details and Competitors
    Table OXiGENE, Inc. Company Details and Competitors
    Figure Global Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (%) Forecast (2017-2022)
    Figure Global Neuroendocrine Tumor Drug Revenue (Million USD) and Growth Rate Forecast (2017-2022)
    Figure Global Neuroendocrine Tumor Drug Price (USD/Pcs) Trend Forecast (2017-2022)
    Table Global Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by Regions (2017-2022)
    Table Global Neuroendocrine Tumor Drug Sales Volume Share Forecast by Regions (2017-2022)
    Figure Global Neuroendocrine Tumor Drug Sales Volume Share Forecast by Regions (2017-2022)
    Figure Global Neuroendocrine Tumor Drug Sales Volume Share Forecast by Regions in 2022
    Table Global Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by Application (2017-2022)
    Figure Global Neuroendocrine Tumor Drug Sales Volume Market Share Forecast by Application (2017-2022)
    Figure Global Neuroendocrine Tumor Drug Sales Volume Market Share Forecast by Application in 2022
    Table Global Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by R protein inhibitors (2017-2022)
    Figure Global Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by R protein inhibitors (2017-2022)
    Figure Global Neuroendocrine Tumor Drug Sales Volume Market Share Forecast by R protein inhibitors in 2022
    Table Global Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by osine kinase 3 inhibitors (2017-2022)
    Figure Global Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by osine kinase 3 inhibitors (2017-2022)
    Figure Global Neuroendocrine Tumor Drug Sales Volume Market Share Forecast by osine kinase 3 inhibitors in 2022
    Table Global Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by atostatin receptor antagonists (2017-2022)
    Figure Global Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by atostatin receptor antagonists (2017-2022)
    Figure Global Neuroendocrine Tumor Drug Sales Volume Market Share Forecast by atostatin receptor antagonists in 2022
    Table Global Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by wth hormone releasing factor a (2017-2022)
    Figure Global Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by wth hormone releasing factor a (2017-2022)
    Figure Global Neuroendocrine Tumor Drug Sales Volume Market Share Forecast by wth hormone releasing factor a in 2022
    Table Global Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by atostatin receptor agonists (2017-2022)
    Figure Global Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by atostatin receptor agonists (2017-2022)
    Figure Global Neuroendocrine Tumor Drug Sales Volume Market Share Forecast by atostatin receptor agonists in 2022
    Figure United States Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (%) Forecast (2017-2022)
    Figure United States Neuroendocrine Tumor Drug Revenue (Million USD) and Growth Rate Forecast (2017-2022)
    Figure United States Neuroendocrine Tumor Drug Price (USD/Pcs) Trend Forecast (2017-2022)
    Table United States Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by Regions (2017-2022)
    Table United States Neuroendocrine Tumor Drug Sales Volume Share Forecast by Regions (2017-2022)
    Figure United States Neuroendocrine Tumor Drug Sales Volume Share Forecast by Regions (2017-2022)
    Figure United States Neuroendocrine Tumor Drug Sales Volume Share Forecast by Regions in 2022
    Table United States Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by Application (2017-2022)
    Figure United States Neuroendocrine Tumor Drug Sales Volume Market Share Forecast by Application (2017-2022)
    Figure United States Neuroendocrine Tumor Drug Sales Volume Market Share Forecast by Application in 2022
    Table United States Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by R protein inhibitors (2017-2022)
    Figure United States Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by R protein inhibitors (2017-2022)
    Figure United States Neuroendocrine Tumor Drug Sales Volume Market Share Forecast by R protein inhibitors in 2022
    Table United States Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by osine kinase 3 inhibitors (2017-2022)
    Figure United States Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by osine kinase 3 inhibitors (2017-2022)
    Figure United States Neuroendocrine Tumor Drug Sales Volume Market Share Forecast by osine kinase 3 inhibitors in 2022
    Table United States Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by atostatin receptor antagonists (2017-2022)
    Figure United States Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by atostatin receptor antagonists (2017-2022)
    Figure United States Neuroendocrine Tumor Drug Sales Volume Market Share Forecast by atostatin receptor antagonists in 2022
    Table United States Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by wth hormone releasing factor a (2017-2022)
    Figure United States Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by wth hormone releasing factor a (2017-2022)
    Figure United States Neuroendocrine Tumor Drug Sales Volume Market Share Forecast by wth hormone releasing factor a in 2022
    Table United States Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by atostatin receptor agonists (2017-2022)
    Figure United States Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by atostatin receptor agonists (2017-2022)
    Figure United States Neuroendocrine Tumor Drug Sales Volume Market Share Forecast by atostatin receptor agonists in 2022